Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
View Patent ↗The invention provides compositions containing a fraction isolated or derived from hops and a methylxanthine. The invention additionally provides compositions containing a fraction derived from hops and a curcuminoid. The invention also provides methods of using such compositions to reduce inflammation.
1. A composition for treatment of inflammation comprising reduced isoalpha acid (RIAA) and methylxanthine in a synergistic ratio having a combination index (CI) of less than 1.
2. The composition of claim 1 , wherein the RIAA is derived from hops.
3. The composition of claim 1 , wherein said RIAA is a member of Genus A having the formula:
wherein R′ is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;
and wherein R″ is selected from the group consisting of CH(CH 3 ) 2 , CH 2 CH(CH 3 ) 2 , and CH(CH 3 )CH 2 CH 3 .
4. The composition of claim 1 , wherein said RIAA is a member selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone.
5. The composition of claim 1 , wherein said methylxanthine is selected from caffeine; theobromine; theophylline; aminophylline; doxofylline; pentoxifylline; 8-oxopentoxifylline; 8-oxolisofylline; lisofylline; 1-proparagyl 3,7-dimethyl xanthine; 7-proparagyl 1,3-dimethyl xanthine; 3-proparagyl 1,7-dimethyl xanthine; 1,3,7-triproparagyl xanthine; 3-isobutyl-1-methylxanthine (IBMX); 1,3,7-tripropyl xanthine; 7-benzyl-IBMX; 1-propyl 3,7-dimethyl xanthine; 1,3-dipropyl 7-methyl xanthine; 1,3-dipropyl 7-proparagyl xanthine; 3,7-dimethyl 1-propyl xanthine; and 7-allyl 1,3-dimethyl xanthine.
6. The composition of claim 1 , wherein the methylxanthine is caffeine.
7. The composition of claim 1 , wherein the composition comprises about 50 to 7500 mg of the RIAA.
8. The composition of claim 1 , wherein the composition comprises about 0.001 to 10 weight percent of the RIAA.
9. The composition of claim 8 , wherein the composition comprises about 0.1 to 1 weight percent of the RIAA.
10. The composition of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.
11. The composition of claim 1 , wherein the composition is formulated for administration orally, topically, parenterally, or rectally.
12. The composition of claim 1 , wherein the RIAA and the methylxanthine are in a ratio of about 100:1 to about 1:100.
13. The composition of claim 1 , wherein the composition comprises about 0.5 to 10,000 mg of the RIAA.